For business leaders, corporate strategists, and growth-focused teams – this report delivers deep market intelligence, forecasts, segmentation, and competitor insights to guide your decisions through 2034.
What is the forecasted revenue size of the dengvaxia industry by 2029?
The dengvaxia market size has grown rapidly in recent years. It will grow from $181.23 million in 2024 to $213.36 million in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to government health initiatives, growing public health awareness, the need for preventive measures, rising travel-related dengue cases, and improved healthcare infrastructure.
The dengvaxia market size is expected to see rapid growth in the next few years. It will grow to $404.70 million in 2029 at a compound annual growth rate (CAGR) of 17.4%. The growth in the forecast period can be attributed to rising incidence of dengue outbreaks, increased government funding, collaboration between public and private sectors, growing public awareness of dengue prevention, and enhanced healthcare infrastructure. Major trends in the forecast period include advancements in vaccine technology, ongoing research and development, innovations in vaccine delivery methods, development of new formulations, and better vaccine storage and distribution techniques.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20035&type=smp
Which industry-specific innovations are acting as key drivers for the dengvaxia market?
The high incidence of dengue is expected to propel the growth of the dengvaxia market going forward. Dengue is a viral infection transmitted by Aedes mosquitoes, causing flu-like symptoms, severe pain, and in severe cases, potentially life-threatening complications such as dengue hemorrhagic fever or dengue shock syndrome. The increasing prevalence of dengue is due to climate change, urbanization, increased travel, and expanding mosquito breeding grounds, leading to higher infection rates and greater demand for prevention and treatment. Dengvaxia helps prevent dengue as it is an effective vaccine that stimulates the immune system to produce a protective response against the dengue virus, reducing the risk of infection and severe complications and contributing to better public health outcomes in endemic areas. For instance, in June 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, in 2024 the Americas reported over 9.7 million dengue cases, double the 4.6 million cases in 2023. Puerto Rico declared a public health emergency with 1,498 cases, and 745 cases were reported among U.S. travelers. Therefore, the high incidence of dengue is driving growth in the dengvaxia market.
Which segment currently leads the dengvaxia market in terms of revenue share?
The dengvaxia market covered in this report is segmented –
1) By Type: Dengvaxia, Other Types
2) By Distribution Channel: Hospitals, Clinics, Public Health Programs
3) By Clinical Indication: Prevention In Previously Infected Individuals, Protection In High-Risk Regions, Traveler Immunization, Pediatric And Adolescent Use
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/dengvaxia-global-market-report
Who are the top competitors in the global dengvaxia market?
Major companies operating in the dengvaxia market include Sanofi Pasteur Inc.
What regional dynamics are shaping the future of the global dengvaxia market?
Asia-Pacific was the largest region in the dengvaxia market in 2024. Latin America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengvaxia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
How Can Companies Use The Dengvaxia Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20035
Need Customized Data On Dengvaxia Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/customise?id=20035&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
